EBS

Emergent BioSolutions Inc. [EBS] Stock Forecast

Q: What is Emergent BioSolutions Inc. stock symbol ?

Emergent BioSolutions Inc. is a US stock, located in Gaithersburg of Maryland and trading under the symbol EBS

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

EBS Stock Summary

Earnings have grown 15.26% per last year.

Earnings are expected to rise 54.49% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

Profit margins (0.04%) are lower than the previous year (0.13%)

Top EBS Correlated Resources

EBS

Top 10 Correlated ETFs

EBS

Top 10 Correlated Stocks

EBS

In the News

12:48 08 Dec 2022 EBS

Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag

The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.

09:02 08 Dec 2022 EBS

4 Toxic Stocks More So Hazardous Amid Volatile Times

Just like identifying stocks with growth potential, pinpointing toxic stocks and offloading them at the right time is crucial to guard one's portfolio from big losses. EBS, WDC, TWKS and DZSI are a few such toxic stocks.

12:02 08 Dec 2022 EBS

Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates

Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services

09:47 08 Dec 2022 EBS

Emergent BioSolutions Inc. (EBS) Q3 2022 Earnings Call Transcript

Emergent BioSolutions Inc. (NYSE:EBS ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President & Chief Executive Officer Rich Lindahl - Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Keay Nakae - Chardan Brandon Folkes - Cantor Operator Good day and thank you for standing. Welcome to the Emergent BioSolutions Third Quarter 2022 Earnings Conference Call.

09:04 08 Dec 2022 EBS

Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -2,016.67% and 10.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

02:05 08 Dec 2022 EBS

Ranking the 7 Top Small-Cap Stocks to Buy From Best to Worst

These top small-cap stocks to buy present daring investors with significant upside. Fundamentally, companies with a relatively diminutive profile typically command higher growth potential.

06:30 08 Dec 2022 EBS

Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022

GAITHERSBURG, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2022, recent business developments, and financial outlook for full year 2022.

12:48 08 Dec 2022 EBS

Emergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?

11:40 08 Dec 2022 EBS

3 Top Monkeypox Stocks to Buy Right Now

With the latest outbreak now reported in all 50 states per ABC News, investors may want to consider the top monkeypox stocks to buy right now. From an investment perspective, this latest health threat poses powerful catalysts.

06:30 08 Dec 2022 EBS

Emergent BioSolutions to Participate in Investor Conferences

GAITHERSBURG, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following investor conferences:

EBS Financial details

Company Rating

Buy

Market Cap

598.66M

Income

53.5M

Revenue

1.51B

Book val./share

29.04

Cash/share

4.83

Dividend

Dividend %

Employees

2.42K

Optionable

Shortable

Yes

Earnings

09 Jan 2023

P/E

7.33

Forward P/E

PEG

-0.85

P/S

0.41

P/B

0.43

P/C

2.62

P/FCF

9.77

Quick Ratio

1.61

Current Ratio

4.17

Debt / Equity

0.71

LT Debt / Equity

0.71

EPS (TTM)

0.82

EPS next Y

12.72

EPS next Q

4.44

EPS this Y

-25.39%

EPS next Y

1451.22%

EPS next 5Y

1451.22%

EPS last 5Y

16.89%

Revenue last 5Y

26.16%

Revenue Q/Q

-1.11%

EPS Q/Q

34.51%

SMA20

-33.33%

SMA50

-42.86%

SMA100

-61.29%

Inst Own

80.25%

Inst Trans

-0.3%

ROA

ROE

ROC

0.06%

Gross Margin

55%

Oper. Margin

11%

Profit Margin

Payout

Shs Outstand

49.89M

Shs Float

44.8M

Target Price

51.5

52W Range

11.34-52.28

52W High

-75.65%

52W Low

+15.09%

RSI

Rel Volume

0.59

Avg Volume

796.23K

Volume

470.43K

Perf Week

2.93%

Perf Month

-39.34%

Perf Quarter

-56.57%

Perf Half Y

-58.9%

Beta

1.037

Volatility

0.3%, 3.59%

Prev Close

2.26%

Price

12.66

Change

4.46%

EBS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
Revenue per share	13.41	15.62	21.48	29.51	34.02
Net income per share	1.98	1.25	1.06	5.79	4.38
Operating cash flow per share	4.98	0.83	3.65	10.17	6.09
Free cash flow per share	3.67	-0.6	1.96	7.5	1.82
Cash per share	4.26	2.24	3.26	11.79	10.93
Book value per share	21.82	20.18	21.14	27.46	30.72
Tangible book value per share	17.78	-1.21	1.55	9.81	14.98
Share holders equity per share	21.82	20.18	21.14	27.46	30.72
Interest debt per share	0.48	16.06	16.5	17.19	16.61
Market cap	2.08B	3.03B	2.84B	5.63B	2.39B
Enterprise value	1.92B	3.72B	3.49B	5.88B	2.65B
P/E ratio	25.24	48.37	52.14	18.46	10.34
Price to sales ratio	3.72	3.88	2.57	3.62	1.33
POCF ratio	10.02	72.56	15.12	10.51	7.43
PFCF ratio	13.6	-100.1	28.11	14.26	24.84
P/B Ratio	2.29	3	2.61	3.89	1.47
PTB ratio	2.29	3	2.61	3.89	1.47
EV to sales	3.42	4.75	3.15	3.78	1.48
Enterprise value over EBITDA	11.44	24.19	15.39	10.64	5.61
EV to operating cash flow	9.23	88.89	18.54	10.98	8.26
EV to free cash flow	12.52	-122.62	34.47	14.9	27.6
Earnings yield	0.04	0.02	0.02	0.05	0.1
Free cash flow yield	0.07	-0.01	0.04	0.07	0.04
Debt to equity	0.01	0.78	0.73	0.58	0.5
Debt to assets	0.15	0.55	0.53	0.5	0.45
Net debt to EBITDA	-0.98	4.44	2.84	0.46	0.56
Current ratio	4.85	3.1	3.17	3.11	3.4
Interest coverage	18.86	9.07	2.97	13.86	10.22
Income quality	2.52	0.67	3.45	1.76	1.39
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.26	0.26	0.25	0.19	0
Research and developement to revenue	0.17	0.18	0.2	0.15	0.13
Intangibles to total assets	0.16	0.48	0.43	0.32	0.28
Capex to operating cash flow	-0.26	-1.72	-0.46	-0.26	-0.7
Capex to revenue	-0.1	-0.09	-0.08	-0.09	-0.13
Capex to depreciation	-1.29	-1.16	-0.79	-1.23	-1.82
Stock based compensation to revenue	0.03	0.03	0.02	0.03	0.02
Graham number	31.14	23.84	22.43	59.8	55.03
ROIC	0.13	0.04	0.05	0.17	0.14
Return on tangible assets	0.09	0.05	0.04	0.16	0.11
Graham Net	4.82	-15.97	-14.63	-9.26	-7.26
Working capital	385.32M	420.4M	469.9M	811.4M	898.3M
Tangible asset value	743.62M	-60.4M	80M	517.2M	789.5M
Net current asset value	327.53M	-597.7M	-552.6M	-240.3M	-67.9M
Invested capital	0.01	0.79	0.75	0.6	0.52
Average receivables	188.49M	251M	253.1M	230.9M	252.8M
Average payables	88.93M	108.4M	115.45M	136.1M	132.5M
Average inventory	224.91M	256.4M	264.75M	307M	328.9M
Days sales outstanding	95.07	126.47	90.85	54.18	55.93
Days payables outstanding	77.87	91.39	79.82	94.8	62.11
Days of inventory on hand	266.35	233.07	187.34	213.85	169.03
Receivables turnover	3.84	2.89	4.02	6.74	6.53
Payables turnover	4.69	3.99	4.57	3.85	5.88
Inventory turnover	1.37	1.57	1.95	1.71	2.16
ROE	0.09	0.06	0.05	0.21	0.14
Capex per share	-1.31	-1.44	-1.69	-2.68	-4.27

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric	2021-09-30	2021-12-31	2022-03-31	2022-06-30	2022-09-30
Revenue per share	6.13	13.52	6.07	4.85	4.81
Net income per share	-0.61	3.54	-0.07	-1.13	-1.52
Operating cash flow per share	0.31	6.15	-0.74	-0.31	-1.48
Free cash flow per share	-0.72	5.28	-1.37	-0.95	-2.04
Cash per share	7.52	10.77	8.6	7.16	4.83
Book value per share	28.36	30.26	31.07	30.26	29.04
Tangible book value per share	11.87	14.76	14.99	14.23	10.05
Share holders equity per share	28.36	30.26	31.07	30.26	29.04
Interest debt per share	15.96	15.89	16.59	16.66	21.28
Market cap	2.69B	2.33B	2.08B	1.55B	1.05B
Enterprise value	3.13B	2.59B	2.48B	2.02B	1.86B
P/E ratio	-20.56	3.07	-140.66	-6.88	-3.46
Price to sales ratio	8.17	3.22	6.77	6.39	4.36
POCF ratio	161	7.07	-55.81	-99.49	-14.15
PFCF ratio	-69.84	8.24	-29.95	-32.54	-10.28
P/B Ratio	1.77	1.44	1.32	1.03	0.72
PTB ratio	1.77	1.44	1.32	1.03	0.72
EV to sales	9.53	3.58	8.06	8.32	7.75
Enterprise value over EBITDA	-712.24	8.47	70.23	-66.2	-80.51
EV to operating cash flow	187.66	7.87	-66.46	-129.43	-25.13
EV to free cash flow	-81.4	9.18	-35.67	-42.33	-18.25
Earnings yield	-0.01	0.08	0	-0.04	-0.07
Free cash flow yield	-0.01	0.12	-0.03	-0.03	-0.1
Debt to equity	0.54	0.5	0.51	0.52	0.71
Debt to assets	0.47	0.45	0.43	0.45	0.5
Net debt to EBITDA	-101.16	0.87	11.25	-15.31	-35.17
Current ratio	3.04	3.4	4.42	3.92	4.17
Interest coverage	-4.13	30.82	0.78	-9.23	-4.94
Income quality	-0.51	1.74	10.08	0.28	0.98
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.15	0.11	0.15	0.21	0.16
Intangibles to total assets	0.31	0.28	0.29	0.29	0.33
Capex to operating cash flow	-3.31	-0.14	0.86	2.06	0.38
Capex to revenue	-0.17	-0.06	-0.1	-0.13	-0.12
Capex to depreciation	-1.69	-1.6	-1.04	-0.72	-0.86
Stock based compensation to revenue	0.03	0.01	0.03	0.05	0.05
Graham number	19.71	49.08	7.14	27.71	31.49
ROIC	-0.01	0.11	0	-0.03	-0.02
Return on tangible assets	-0.02	0.09	0	-0.03	-0.04
Graham Net	-10.57	-7.15	-8.53	-10.4	-16.07
Working capital	746.1M	898.3M	851.1M	807.5M	850.1M
Tangible asset value	637.6M	789.5M	759.8M	711.7M	501.7M
Net current asset value	-233.3M	-67.9M	-104.8M	-138M	-340.7M
Invested capital	0.56	0.52	0.53	0.55	0.73
Average receivables	214.8M	224.85M	178.4M	175M	183.15M
Average payables	120.7M	117.55M	106.75M	106.2M	105M
Average inventory	395.05M	388.15M	413.1M	425.5M	485.9M
Days sales outstanding	69.65	34.19	53.21	64.89	71.74
Days payables outstanding	55.94	54.49	61.94	56.29	62.87
Days of inventory on hand	150.87	148.29	231.32	225.53	330.87
Receivables turnover	1.29	2.63	1.69	1.39	1.25
Payables turnover	1.61	1.65	1.45	1.6	1.43
Inventory turnover	0.6	0.61	0.39	0.4	0.27
ROE	-0.02	0.12	0	-0.04	-0.05
Capex per share	-1.03	-0.87	-0.64	-0.64	-0.56

EBS Frequently Asked Questions

What is Emergent BioSolutions Inc. stock symbol ?

Emergent BioSolutions Inc. is a US stock , located in Gaithersburg of Maryland and trading under the symbol EBS

Is Emergent BioSolutions Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $51.5. The lowest prediction is $38 and the highest is $65

What is EBS stock prediction ?

What is Emergent BioSolutions Inc. stock quote today ?

Emergent BioSolutions Inc. stock price is $12.66 today.

Is Emergent BioSolutions Inc. stock public?

Yes, Emergent BioSolutions Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 796.23K
Market Capitalization 598.66M
Employee 2.42K
CEO Mr. Robert Kramer
Headquarters Gaithersburg,MARYLAND,US
IPO Date 2006-11-15
Website https://www.emergentbiosolutions.com

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.